Physiological levels of Kras G12D are sufficient to induce pancreatic intraepithelial neoplasias (PanINs); the mechanisms that drive PanIN progression are unknown. Here, we establish that, in addition to oncogenic Kras G12D , IL-6 transsignaling-dependent activation of Stat3/Socs3 is required to promote PanIN progression and pancreatic ductal adenocarcinoma (PDAC). Myeloid compartment induces Stat3 activation by secreting IL-6; consequently, IL-6 transsignaling activates Stat3 in the pancreas. Using genetic tools, we show that inactivation of IL-6 transsignaling or Stat3 inhibits PanIN progression and reduces the development of PDAC. Aberrant activation of Stat3 through homozygous deletion of Socs3 in the pancreas accelerates PanIN progression and PDAC development. Our data describe the involvement of IL-6 transsignaling/Stat3/Socs3 in PanIN progression and PDAC development.
INTRODUCTION
Despite the considerable efforts that have been made in basic and clinical research, pancreatic ductal adenocarcinoma (PDAC) affects 230,000 patients in the Western Hemisphere annually. PDAC is notable for its high mortality, constituting the fourth leading cause of death due to cancer (Hidalgo, 2010) .
Recent efforts have helped identify the molecular genetic determinants of PDAC. Activating KRAS mutations have been detected in 30% of pancreatic intraepithelial neoplasias (PanINs), which are precursor lesions, increasing to 100% in advanced PDACs. Inactivation of INK4A and TRP53 occurs later during PanIN progression and PDAC formation (Hruban et al., 2006) .
These findings have been mirrored in mouse models. Pancreas-specific expression of mutations (Kras G12D , Kras G12V ,
Kras

G12D
, Trp53 R172H ) or deletion of tumor suppressor genes (Trp53, Ink4A/Arf) in genetically engineered mice (GEM) recapitulates PanIN initiation and progression to pancreatic cancer (PC), similar to the clinical pathology (Aguirre et al., 2003; Guerra et al., 2007; Hingorani et al., 2003 Hingorani et al., , 2005 Kelly et al., 2008) . Although it has been studied in GEM for pancreatic cancer, the role of concomitant stromal reactions (stromal desmoplasia) in PanIN progression and cancer development has not been addressed; most existing concepts have merely been inferred. The presence of stromal desmoplasia is a hallmark of PDAC (Algul et al., 2007b) , forming a unique microenvironment that comprises many cell types, including proliferating fibroblasts and pancreatic stellate cells that produce and deposit fibronectin and collagen, and inflammatory cells and macrophages that release chemokines and cytokines. In particular, the function of concomitant inflammation in PDAC has garnered recent interest, because proinflammatory markers in the serum, such as interleukin (IL)-1b and IL-6, are associated with outcomes in PDAC (Ebrahimi et al., 2004; Sawai et al., 2003) . Additionally, chronic pancreatitis is a risk factor for PDAC, supporting the involvement of concomitant inflammation in pancreatic oncogenesis (Lowenfels et al., 1993) .
Dysregulated activation of signal transducer and activator of transcription (Stat) family members occurs often in many human malignancies. Of the seven Stat proteins, activation of Stat3 in cancer is related to tumor growth directly through tumor-autonomous mechanisms and indirectly by modulating tumor-associated stroma and the immune system. Activation depends on the phosphorylation of a conserved tyrosine residue (Y705) by upstream kinases, such as Janus kinase 2 (Jak2). Jak2 activation requires activation of the ubiquitously expressed gp130 receptor by specific ligands (IL-6, leukemia inhibitor factor [LIF] , oncostatin M [OSM] , ciliary neurotrophic factor [CNTF] , .
Of these ligands, IL-6 has the unique capacity to activate Stat3 using two modes. The first mode entails classical signaling mechanisms, characterized by the binding of IL-6 to the IL-6 receptor (IL-6R) and gp130 on specific target cells. However, a few subsets of cells, such as monocytes/macrophages and hepatocytes, express the membrane-bound IL-6R, whereas gp130 is ubiquitously expressed. Alternatively, IL-6 binds to a naturally occurring soluble form of IL-6R (sIL-6R), forming a complex that induces IL-6-specific signaling in cells that lack membrane-bound IL-6R, a process that is called IL-6 transsignaling. In humans, sIL-6R is generated either by alternative splicing or by proteolytic release of the ectodomain of the membrane-bound IL-6R, whereas in the mouse, sIL-6R is exclusively generated by proteolysis (Rose-John and Heinrich, 1994) . All of these events result in the dimerization of phosphorylated Stat3 monomers via Src homology-2 (SH2) domains, shifting them into a transcriptionally active conformation. Stat3 regulates its own endogenous inhibitor, Socs3, to form a negative feedback loop .
Stat3 activation in PDAC has been documented in human tissues and pancreatic cancer cell lines, although the mechanism of Stat3 activation in the absence of JAK2 mutations and its function in pancreatic oncogenesis has not been examined (Kocher et al., 2007; Scholz et al., 2003) .
In the present study, we aim to identify the role of the IL-6 dependent Stat3 signaling pathway in pancreatic cancer using genetically engineered mouse models.
RESULTS
Non-Cell-Autonomous Activation of Stat3
Y705
in Pancreatic Cancer Although Stat3 activation occurs in human PanIN, PC, and pancreatic cancer cell lines, its function in pancreatic carcinogenesis has not been examined (Scholz et al., 2003) . First, we determined whether this finding could be repeated in Kras G12D mice. Kras G12D mouse lines express a constitutively active form of mutated K-Ras in the pancreas, thereby recapitulating the entire spectrum of pancreatic carcinogenesis that is observed in humans (Hingorani et al., 2003) . Phosphorylation of Stat3 Y705 was analyzed in four PDACs (ID 14128, 9907, 17027, 16069 ) (see Table S1 Figure 1C ) and their metastases ( Figure 1D ) in contrast to normal pancreas (LSL-Kras
G12D
) ( Figure 1B ), similar to findings in humans. Notably, p-Stat3 Y705 was restricted to malignant cells ( Figure 1B , black stars) and infiltrating cells (Figure 1B, black arrows) or hepatocytes ( Figure 1B , white arrows) that surrounded the metastasis. These data suggest that the level of Stat3 activation correlates with the progression of PanINs to PDAC. Moreover, Stat3
Y705 phosphorylation is restricted to malignant cells and cells in the microenvironment.
To examine the mechanism of Stat3 activation in vitro, we generated cell lines from primary (pancreas) and metastatic (liver, lung, ascites) tumors (ID 9907, 16069, 17027; see Table  S1 ). In contrast to their primary tumors or metastases, the isolated cancer cell lines showed low-level Stat3 activation in vitro or none at all ( Figure 1E ; for ID numbers, see Table S1 ). This observation is consistent with non-cell-autonomous phosphorylation of Stat3. Likely, Stat3 phosphorylation depends on the microenvironment of the PDAC.
To determine the mechanisms and factors through which Stat3 is phosphorylated in vivo, we measured the expression of gp130 ligands (IL-6, LIF, OSM, CNTF, IL-11) in the pancreas of Kras G12D mice, because these ligands activate the Stat3 cascade. Only IL-6 mRNA levels increased robustly and time dependently ( Figure 2A) ; the levels of LIF, OSM, CNTF, and IL-11 remained unchanged or rose slightly ( Figure S1A ). The primary cancer cell lines that were derived from Kras G12D mice (ID 14128) responded to IL-6, experiencing strong phosphorylation of Stat3 ( Figure 2B ). Due to its high expression in nontumor Kras G12D mice and its abilty to activate the Stat3 cascade in PDAC cell lines, we determined the cellular source of IL-6. By IHC, IL-6 was expressed predominantly by infiltrating immune cells ( Figure 2C , white arrow); acinar cells expressed low levels ( Figure 2C , black star). These pancreatic infiltrates in Kras G12D mice comprised ) in the pancreas during acute pancreatitis. Acute pancreatitis was induced by repetitive hourly injections of cerulein. Pancreata from three C57BL/6 mice were pooled and analyzed by FACS. Means ± SD (n = 3), **p < 0.005. Scale bars equal 50 mM. See also Figure S1 .
primarily F4/80-positive macrophages and rare CD3-positive ( Figures 2H-2J ) as the chief component of the cellular infiltrate and the source of IL-6 during pancreatic oncogenesis.
IL-6 Transsignaling Promotes PanIN Progression
Based on these findings, we hypothesized that Stat3 activation in pancreatic oncogenesis depends on the microenvironment, particularly on myeloid cells that secrete the gp130 ligand IL-6. To examine the interaction between macrophages and acinar cells that harbor Kras
G12D
, we developed a coculture system in which macrophages were isolated from the pancreas of 18 week old Kras G12D mice and incubated with acinar cells derived from Kras G12D mice. Even prestimulation of the macrophages with IL-6 was insufficent to induce robust Stat3 activation in Kras G12D acinar cells. These data suggest that factors other than IL-6 are required to activate Stat3 in acinar cells from Kras G12D mice ( Figure S2A ).
IL-6 signals are transmitted via gp130 through IL-6 engagement of IL-6R or formation of a complex with soluble IL-6R, that latter of which is called IL-6 transsignaling. To determine the effects of IL-6 on the pancreas, we extended our in vitro analysis in acinar cells that were isolated from Kras G12D mice.
As shown in Figure 3A , only the IL-6R/IL-6 complex (termed as Hyper-IL-6) induced robust phosphorylation of Stat3 in acinar cells; IL-6 resulted only in slight phosphorylation. These data suggest that acinar cells require IL-6 transsignaling, rather than classical IL-6 signaling, to activate Stat3 in response to IL-6.
To characterize the impact of classical and IL-6 transsignaling on PanIN progression in vivo, Kras G12D mice were interbred with Figure S2B . As shown in Figure S2C , reconstitution of Kras G12D mice with IL-6-competent (Il-6 Collectively, these data suggest that myeloid cells use IL-6 transsignaling rather than classical IL-6 signaling to promote PanIN progression. The downstream effector Stat3 appears to be associated with the development of PanIN lesions.
Stat3 Constitutes a Central Node that Mediates PanIN Progression and PDAC Development
Because Stat3 is considered the major protumorigenic effector of IL-6, we determined the contribution of pancreatic Stat3 to PanIN progression and PC development. By immunofluorescence, we observed early phosphorylation of Stat3 at tyrosine residue 705 in the pancreas of 13-week-old Kras G12D mice (Figures 4A-4C, white star) and in infiltrating macrophages ( Figures 4A-4C , white arrows). In parallel, the expression of bona fide Stat3 target genes increased in the pancreas of these mice (data not shown). The widespread phosphorylation of Stat3 in the pancreas clearly suggested paracrine/autocrine stimulation rather than a cell-autonomous effect.
To examine the effect of Stat3 activation in the exocrine pancreas during oncogenesis, we generated compound mutant Kras G12D mice that lacked phosphorylatable Stat3 Y705 specifically in the exocrine pancreas and parts of the endocrine compartment using the Ptf1a-cre ex1 mouse line (Kras
G12D ;Stat3
Dpanc ) (Algul et al., 2007a; Nakhai et al. 2007; Sano et al., 1999) . Stat3 inactivation had no effect on pancreatic development in adult mice, and basal proliferation rate and apoptotic index were indistinguish- Figure 4P , white arrow) and low-grade PanIN lesions (PanIN-1) ( Figure 4R , black arrow) were detectable in 13 and 18 week old mice, suggesting that Stat3 inactivation in the pancreas prevents PanIN progression but not its initiation ( Figure 4S ). To determine whether Stat3 inactivation influences PDAC development, we followed two cohorts, 20 Kras G12D and 41
Kras
G12D
;Stat3 Dpanc mice, for nearly two years (Table 1; Table   S1 ). Figure S3D ) because they failed to phosphorylate Stat3. Consequently, proliferation was delayed after incubation with various concentrations of FCS ( Figure S3E ) and IL-6 (Figures S3F). Similar results were obtained when these cell lines were incubated with Hyper-IL-6 (data not shown). These cell lines expressed a slightly smaller version of Stat3, termed as Stat3
Dpanc . Collectively, our data suggest that epithelial Stat3 is required for the transduction of tumor-promoting signals of IL-6, particularly during the progression of PanIN to PDAC, but not in the initiation of PanIN. Figure S4A ) ).
Stat3 Regulates Cell-Autnomous Effects during Pancreatic Oncogenesis in
To determine whether Stat3 regulates proliferation in the pancreas of Kras G12D mice, we injected mice with 5-bromo-2-deoxyuridine (BrdU), which incorporates into newly synthesized DNA, and sacrificed the animals two hours later. By anti-BrdU staining, we observed the time-dependent incorporation of BrdU into acinar and ductal cells (data not shown), but mice that were deficient for phosphorylable Stat3 Y705 expressed
fewer BrdU-positive cells in the pancreas, even after 13 weeks of age ( Figure 5D ). Consistent with this result, proliferating cell nuclear antigen (PCNA) expression was generally higher in Kras G12D mice ( Figure 5E ). Next, we identified proteins that were expressed during proliferation by generating pancreatic protein lysates from 9 and 13 week old Kras G12D Figure 5E ). pLN, peripancreatic lymph node; M, metastasis; pC, pancreatic cyst; U, undifferentiated; G, glandular; A, atrophy; SD, skin disease; BO, biliary obstruction; P, paralysis.
Further, Stat3 seems to be involved in concomitant inflammation in the pancreas, as the accumulation of F4/80-positive macrophages declined in Stat3-proficient mice ( Figures S4B  and S4C ). In addition, the Stat3-dependent and proinflammatory enzyme Cox-2 was not expressed in Kras
G12D
;Stat3
Dpanc mice compared with Kras G12D animals ( Figure S4D ). Cox-2 was detectable in acinar cells and in ductal lesions ( Figures S4E  and S4F ). Based on our data, we conclude that Stat3 activation regulates Kras
G12D
-dependent effects on apoptosis, proliferation, and inflammation.
Homozygous Deletion of Socs3 Accelerates PanIN Progression and Promotes PDAC Development
Although Stat3 regulates PanIN progression, it is unknown whether Stat3 alone is sufficient to mediate these effects. Stat3 activation is tightly regulated by the endogenous feedback inhibitor Socs3, which inhibits Stat3 signaling by binding to gp130.
Kras G12D mice expressed high levels of Socs3 mRNA (Figure 6A) . Socs3 was detectable in acinar cells ( Figure 6B , black arrows) and PanIN lesions ( Figure 6B , white arrows) of Kras G12D mice.
To induce early and prolonged activation of p-Stat3 Y705 in the pancreas of these mice, we generated a mutant mouse line that lacked Socs3 specifically in the pancreas (Nakaya et al., 2009 Figure 6K ) and low-( Figure 6H ) and high-grade ( Figure 6E ) PanINs throughout the pancreas ( Figure 6D ). The nuclei of ductal lesions and acinar cells were positive for phosphorylated Stat3 Y705 ( Figures 6F-6L ) and Cyclin D1 ( Figures   6G-6M ). By quantification of ductal lesions, we observed rapid progression of PanINs in these mice ( Figure 6N ). (Table S2 ). The combination of activated Kras G12D and Socs3 deficiency led to significant decreases in body and pancreatic weight (data not shown). As shown in Figure (Table S2 ). These ductal adenocarcinomas ( Figure 6P ) were positive for CK-19 ( Figure 6Q ) and p-Stat3 Y705 ( Figure 6R ). Phosphorylated Stat3 Y705 was restricted primarily to the nuclei of cancer cells ( Figure 6S ). Tumor latency in these mice was lower compared with Kras G12D mice (93 vs 428 days, Figure 6T ).
Collectively, these results suggest that levels of Stat3 phosphorylation determine the progression of PanIN lesions to pancreatic cancer.
Evidence for the IL-6/Stat3 Cascade in Human PDAC To determine the relevance of the observed link between myeloid IL-6 and p-Stat3 Y705 in PDAC, we measured IL-6 and soluble IL-6-receptor (sIL-6R) levels in patients with PDAC. Serum IL-6 levels in 39 patients were significantly higher than in healthy control groups ( Figure 7A ), and sIL-6R levels did not differ ( Figure 7B ). Based on the the significantly high systemic levels of IL-6 and the presence of sIL-6R in patients, we examined whether the IL-6/Stat3 cascade was detectable locally in human specimens ( Figures 7C and 7D ) by performing the IHC of p-Stat3 Y705 and IL-6 in human specimens of PDAC. Notably, Stat3 was activated in PDAC ( Figure 7E ) and in the acinar cells or early PanIN lesions in tumor-adjacent tissues, similar to the observations in our mouse models ( Figure 7F ). Most infiltrating cells were macrophages by anti-CD68 staining ( Figure 7E ), and CD3-positive (T) Tumor latency in Kras G12D (n = 11) and Kras
G12D
;Socs3 Dpanc (n = 12) cohorts. Means ± SD, ***p < 0.0005.
Scale bars equal 500 mM (D) and 50 mM (B, E-M, and P-R). See also Table S2 . lymphocytes were scattered around cancer cell clusters and preneoplastic lesions (Figures 7G and 7H) . In tumor-adjacent tissues, macrophages were observed between nontransformed acini ( Figure 7I ). By immunofluorescence, macrophages were determined to be the principal source of IL-6 (Figures 7K-7N) .
Collectively, these data suggest that the basis for classical IL-6 and IL-6 transsignaling, linking myeloid IL-6 to p-Stat3 Y705 in preneoplastic or neoplastic cells, exists in human PDAC and potentially define a mechanism of pancreatic oncogenesis.
DISCUSSION
Aberrant activation of Stat3 in the absence of Jak2 mutations is a recurring theme in human PDAC; however, its implication in pancreatic oncogenesis in vivo has remained undetermined (Glienke et al., 2010; Hutzen et al., 2009; Lin et al., 2010b; Scholz et al., 2003) . Using genetic and pharmacological tools, we identified important functions of IL-6 and Stat3 and their implications for multiple aspects of pancreatic oncogenesis.
Also, we detailed a signaling network between stromal and preneoplastic pancreatic cells and identified Stat3 as the critical node in this interplay. Our study provides evidence that myeloid cells release IL-6 to induce Stat3 activation in the pancreas via IL-6 transsignaling, thus potentiating a feed-forward response in the tumor microenvironment to promote PanIN progression and, ultimately, PDAC development in vivo. Genetic inactivation of classical IL-6 signaling, IL-6 transsignaling, and the Stat3 effector pathway impaired PanIN progression and PDAC development ( Figure 7O) .
By identifying the underlying mechanisms, we have explained the implications of IL-6 and myeloid cells in human PDAC mechanistically. Many studies have observed a robust and consistent assocation of IL-6 with patient outcomes (Ebrahimi et al., 2004; Talar-Wojnarowska et al., 2009) , and a specific polymorphism of IL-6 has been reported to be overrepresented in such patients (Talar-Wojnarowska et al., 2009) . The density of inflammatory cells in pancreatic carcinoma, especially of macrophages, has predictive value for patient prognoses (Kurahara et al., 2009) .
In this study, we found that pancreatic myeloid cells mediate tumor promotion substantially by releasing IL-6 into the stroma. Consistent with this observation, enhanced pancreatic inflammation in Kras G12D mice through repetitive application of the hormone cerulein accelerates PanIN progression and PDAC development, underscoring the significance of inflammatory cells in these settings (Guerra et al., 2007) . Because cerulein fails to induce phosphorylation of Stat3 in acinar cells derived from Kras G12D mice in vitro, we assume that inflammatory cells release IL-6 to induce p-Stat3 in the pancreas, thus promoting oncogenesis in this inflammation-associated model of PDAC. The paracrine effects of IL-6, however, are not restricted to preneoplastic and cancer cells in the pancreas. We observed Stat3 activation in infiltrating macrophages and normal hepatocytes that surrounded metastatic lesions, suggesting a general effect of IL-6 on the various cells that constitute the microenvironment; whether this activation in nontransformed cells impacts oncogenesis or the formation of metastatic lesions is unknown.
The IL-6/Stat3 cascade appears to be ubiquitous-not restricted solely to the pancreas. In a model of inflammationassociated colorectal carcinogenesis, for example, myeloid IL-6 activates Stat3 to promote the formation of adenoma and tumors (Bollrath et al., 2009; Grivennikov et al., 2009) . Our data do not exclude the involvement of other cytokines, because transgenic overexpression of Il-1beta in the pancreas has been shown to be sufficent to induce proliferation, robust desmoplasia, and rare acinar-ductal metaplasia (Marrache et al., 2008) . Notably, IL-1b failed to acitvate Stat3 in pancreatic cancer cells, suggesting that other signaling pathways transmit its signals in the pancreas.
Although the involvement of IL-6 in cancer-promoting inflammation in various organs is well established, no study has implicated IL-6 or IL-6 transsignaling in spontaneous tumor formation. Using the Kras G12D model in the pancreas, we defined a central function for IL-6 during oncogenesis.
Two distinct processes control IL-6 responses in vivo. IL-6 signals are transmitted via gp130 through IL-6 engagement of IL-6R or formation of a complex with soluble IL-6R (i.e., IL-6 transsignaling). Because IL-6R is sparsely expressed, IL-6 transsignaling increases the number of potential IL-6 target cells (Rose-John et al., 2006) . Nontransformed acinar cells that express oncogenic Kras G12D require IL-6 transsignaling to induce robust phosphorylation of Stat3. IL-6 itself is predominantly secreted by inflammatory cells, most likely in an NF-kBdependent manner. Similarily, recruitment of these cells to the pancreas also involves induction of NF-kB, potentially as a consequence of Kras G12D dependent activation (Finco et al., 1997) . Beyond its capacity to secret IL-6, immune cells have also been shown to participate in the process of IL-6R shedding (Chalaris et al., 2007) , a process that also involves the metalloproteinases ADAM17 (a desintegrin and metalloproteinase), and to a lesser extent ADAM10 (Matthews et al., 2003) . In addition to its function as an important regulator of proinflammatory chemokines and cytokines, NF-kB might therefore be implicated in establishing IL-6 transsginaling during pancreatic oncogenesis (Algul et al., 2007c; Guerra et al., 2007) . Whether the metallproteinases ADAM17 and ADAM10 has a role to play, and what role it plays, during pancreatic oncogenesis remains to be elucidated in further studies. Using genetic tools, we herein found that IL-6 transsignaling, not classical IL-6 signaling, entails Stat3 activation to promote PanIN progression in vivo. Thereby, our data extend previous findings implicating immune cells to include myeloid-derived suppressor cells, tumor-associated macrophages, and Treg in PDAC development (Clark et al., 2007) .
The major protumorigenic IL-6 effector is Stat3, the ablation or prolonged activation in the pancreas of which influences PanIN progression but not PanIN initiation. Stat3 has been implicated in apoptosis and cell cycle progression during oncogenic (Kras G12D ) stress. We identified Stat3 activation as the chief mediator of programmed cell death. Stat3 upregulated the antiapoptotic proteins Bcl-X L , Mcl-1, and Survivin, which were recently demonstrated to be Stat3 target genes . Their activity during apoptosis in pancreatic cancer has also been observed.
Inhibition of Stat3 in human pancreatic cancer cells facilitates apoptosis and inhibits chemoresistance (Lin et al. 2010a) . Persistent Stat3 activation during PanIN progression also mediates the proliferation of preneoplastic lesions in the pancreas.
Similarily, deletion of IKK in hepatocytes effects chronic Stat3 activation, inducing proliferation and promoting hepatocellular carcinoma on exposure to diethylnitrosamine . Consistent with this observation, Stat3 inactivation mitigates the incorporation of BrdU in the pancreas, paralleled by impaired induction of Cyclin D1 (Masuda et al., 2002) and c-myc (Barre et al., 2005) , which are regulated by nuclear Stat3 and overexpressed in human specimens of PDAC (Kawesha et al., 2000) . These factors are central in driving cancer cells from G0/G1 to S phase, propelling cell cycle progression. Similarly, isolated pancreatic cancer cell lines from Stat3-deficient Kras G12D mice proliferated less in response to FCS, IL-6, and Hyper-IL-6. Intracellular regulation of Stat3 activation is tightly controlled by the concomitant expression of its endogenous inhibitor, Socs3 (Glienke et al. 2010; Greten et al., 2002; Hutzen et al., 2009; Kim et al. 2010; Lin et al. 2010a; Scholz et al., 2003; Trevino et al., 2006) . One explanation for this discrepancy proposes that additional mutations in p53 in human cancer cell lines mediate constitutive phosphorylation of Stat3, as seen in other tumor cells (Lin et al., 2002) . Wild-type p53 regulates Stat3 phosphorylation in ovarian cancer cell lines (Caov-3 and MDAH2774) by controlling Jak2 through p53-dependent upregulation of protein tyrosine phosphatase 1-B (PTP-1B), which inactivates Jak2 (Reid et al., 2004) . The balance between PTP-1B and Jak2 is likely to be dysregulated in human pancreatic cancer cell lines, because nearly all established human PDAC cell lines harbour p53 mutations (Sipos et al., 2003) . In contrast, such mutations were absent in the cell lines that were derived from Kras G12D mice (data not shown).
We have identified an important mechanism that determines the progression and development of PanIN to PDAC. Kras G12D -induced pancreatic oncogenesis depends on the microenvironment, wherein myeloid cells in the pancreas accelerate PanIN progression and PDAC development by releasing IL-6. In examining the routes of IL-6 dependent activation of Stat3, we have demonstrated a relevant function of IL-6 transsignalling in pancreatic oncogenesis. Through IL-6 transsignaling and Stat3, IL-6 promotes tumor development in the pancreas. Genetic manipulation of IL-6 transsignaling and Stat3 activation impairs PanIN formation and significantly impedes PDAC development. Using patient data and human PDAC specimens, we have demonstrated that this crosslink also exists in the human disease.
EXPERIMENTAL PROCEDURES Mice
The LSL-Kras G12D knockin (Jackson et al., 2001 ), Ptf1a-cre ex1 (Nakhai et al., 2007) , Stat3 F/F (Sano et al., 1999) , sgp130 tg (Rabe et al., 2008) Human Serum IL-6 Measurements Serum samples were obtained from 38 patients with histologically or cytologically confirmed PDCA from whom pretreatment serum samples were available. The analysis group consisted of 15 females (median age 67 years, range 41-81 years) and 23 males (median age 68 years, range 50-80 years). Whole blood was collected prior to administration of chemotherapy. Serological analysis was performed at the Institute for Clinical Chemistry, Technical University, Munich. Control sera were obtained from healthy probands. The Local Ethics Committee approved the analysis, and written informed consent was obtained from all patients and controls.
Quantification of Proliferation, Apoptosis, and Inflammation
Mice were injected intraperitoneally with 50 mg/kg BrdU (Sigma) 2 hr prior to sacrifice, and paraffin sections were stained with anti-BrdU. Apoptosis was measured by immunohistochemistry of cleaved caspase-3. Inflammation was assessed using macrophage markers (F4/80). For each analysis, positive cells were scored in the pancreata from several animals of each genotype.
Flow Cytometry
Pancreata were injected with 1.2 mg/ml collagenase P (Roche) and minced. Single-cell suspensions of pancreatic cells were immunolabeled with fluorochrome-conjugated antibodies in PBS that was supplemented with 2% heatinactivated FBS (Gibco-Invitrogen) and 5 mM EDTA (Sigma). All antibodies were purchased from eBioscience: eFluor 450-conjugated anti-CD45, fluorescein isothiocyanate-conjugated anit-CD19, PE-conjugated anti-F4/80, allophycocyanin-conjugated anti-CD11c, APC-eFluor 780-conjugated antiCD11b, and Alexa Fluor 700-conjugated anti-CD3. Cells were stained with propidium iodide (BD Biosciences) to assess viability. Flow cytometry analysis was performed on a Gallios flow cytometer (Beckman Coulter) after gating and excluding dead cells. Data were analyzed using FlowJo software.
Statistical Analyses
Data are presented as averages ± standard deviaions (SD) and were analyzed by built-in t test using Microsoft Excel. p < 0.05 was considered significant. For the overall survival analysis, Kaplan-Meier curves were analyzed by log rank test. Tumor incidence was analyzed using Fisher's exact test. In all cases, we chose a group size that produced statistically unambiguous results.
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